Pediatric cardiology and adult congenital heart disease  by Murphy, Daniel J
Pediatric Cardiology and Adult Congenital Heart Disease
Daniel J. Murphy, JR, MD
Palo Alto, California
One hundred nine abstracts were presented as posters or
oral presentations covering a wide range of topics encom-
passing all aspects of congenital cardiology from fetal life to
adults with congenital heart disease (ACHD).
One study that was presented from two groups in
Toronto and Montreal described outcomes for 50 fetuses
with complete atrioventricular block in utero. Twenty-two
of those had structural heart disease, and 19 of 22 died. On
the other hand, of 28 with normal cardiac anatomy, 13 had
heart rates 55 beats/min. Seven mothers received treat-
ment beta-sympathomimetics, and only one of the seven
treated fetuses died compared with five of six deaths without
treatment. Seventeen of 24 pregnancies with autoimmune
antibodies were treated with maternal dexamethasone, and
only 3 (18%) did not survive the neonatal period, whereas 4
of 7 cases (57%) without steroid therapy died (1).
One of the most provocative papers described the expe-
rience of a large collaborative group in Boston (2) who
performed balloon dilation of aortic stenosis in 12 fetuses.
The Boston group evaluated 16 fetuses between 22 and 29
weeks gestation who had aortic stenosis and were expected
to develop hypoplastic left heart syndrome. Of the patients
who declined to participate, three of four were born with
hypoplastic left heart syndrome (HLHS), suggesting that
the investigators were able to correctly identify fetuses at
risk for the development of HLHS. Balloon aortic valvot-
omy was attempted in 12 fetuses. Five procedures were
technically unsuccessful: one pregnancy was terminated, one
fetus died in utero, and three patients were born with
HLHS. Of the seven successful aortic valve dilations, three
infants were born with HLHS, two are still in utero at 31
and 23 weeks, and one baby was born with mild aortic
stenosis and has survived to 15 months without interven-
tion. There was no significant maternal morbidity. This
exciting report represents the early results from a large
multidisciplinary team and signals the inauguration of fetal
cardiac intervention.
There were a substantial number of studies in ACHD. A
group at McGill University attempted to assess the preva-
lence of ACHD in Quebec. Using ICD-9 diagnostic codes,
the investigators examined provincial health care records to
identify all ACHD patients older than 18 years in 2000.
They identified 15,339 adults for a total prevalence rate of
2.3/1,000. These data suggest that as many as 500,000
ACHD are alive in the U.S., 10% of whom are expected to
have complex disease (3).
A study from Mayo Clinic (4) described outcomes for
112 pregnancies in 43 women with tetralogy of Fallot. All
but three had undergone complete surgical repair. There
were 29 (26%) spontaneous first trimester miscarriages and
one term stillbirth. Six of 43 patients had cardiovascular
complications: supraventricular tachycardia in 2, congestive
heart failure in 2, pulmonary embolism in 1. There were no
peripartum deaths. Two infants had significant congenital
cardiac defects.
Virtually all individuals with tetralogy of Fallot will face
the prospect of pulmonary valve replacement. T. P. Graham
presented the results of a multicenter retrospective review
sponsored by the International Society for Adult Congenital
Heart Disease in which data were collected for 93 patients
who underwent pulmonary valve replacement. The average
age was 26 years, and follow-up averaged 3 years. There
were no early deaths, and the majority of patients experi-
enced reduction in right ventricular size and ability index.
Kaplan-Meier estimates of durability showed approximately
50% re-replacement at 11 years (5).
Clinical experience with interventional techniques in
congenital heart disease is increasing. Reporting early hu-
man experience, several reports described successful trans-
catheter closure of ventricular septal defects. Atrial septal
defects (ASD) and patent foramen ovale have been closed
via catheter for a number of years. Follow-up studies after
transcatheter ASD closure demonstrated favorable right
heart remodeling in 50 patients older than 60 years (6),
modest improvement in cardiopulmonary exercise capacity
(7), and even relief of migraine headaches (8). Septal closure
devices can be associated with thrombus formation. Sievert
from Frankfurt, Germany (9) performed routine post-
procedure transesophageal echocardiograms at two to four
weeks and six months. Thrombus was found in 20 patients,
associated with three minor strokes and one transient
ischemic attack. Most of the thrombi resolved with admin-
istration of warfarin, but three patients required surgical
thrombectomy. Other midterm complications of ASD de-
vices were reported, including systemic nickel dissemination
(10) and mild aortic insufficiency (11).
The studies presented at this year’s American College of
Cardiology Scientific Sessions demonstrate that short- and
long-term results continue to improve for all forms of
congenital heart disease. New indications, techniques, and
populations provide novel opportunities for intervention
and promise to improve outcomes in the future.
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The angiography and interventional cardiology working
group reviewed 1,095 abstracts for this year’s scientific
sessions and accepted 355. There were five areas of major
impact from the meeting: the use of distal projection
strategies for vein graft intervention and acute myocardial
infarction (AMI), new thromboatherectomy devices, the
role of inflammation in percutaneous coronary intervention
(PCI), new insights on drug-eluting stents, and peripheral
interventions.
DISTAL PROTECTION
In the setting of AMI, Drs. Gibson and Stone have
previously demonstrated that distal emboli and inflamma-
tion in the distal coronary bed predict 30-day and 1-year
mortality, even in the presence of Thrombolysis In Myo-
cardial Infarction grade 3 (TIMI-3) flow. Advancing this
work, Dr. Limbruno presented the Filter Wire Distal
Protection Trial in AMI. This 100-patient study enrolled
patients who presented with ST-segment elevation within
six hours and TIMI-3 flow in a native coronary vessel 3
mm. Patients were randomized to stent with or without the
protection of the distal filter wire. An improvement in
TIMI-3 flow and myocardial blush scores, more rapid
resolution of ST-segment changes, and improvement in
regional wall motion recovery and less distal emboli were
demonstrated in the treated group relative to the control
group. Dr. Stone presented the FIRE trial, comparing the
Filter Wire to the Percusurge Guard wire in saphenous vein
graft (SVG) intervention. This trial was designed as a
non-inferiority trial to the approved Guard Wire System.
Major adverse cardiac events (MACE) at 30 days with the
Filter Wire were equivalent to the Guard Wire, with respect
to death, myocardial infarction (MI), and urgent target
vessel revascularization.
Data were presented on the X-SIZER catheter, a throm-
boatherectomy device in AMI. Dr. Reimers and colleagues
randomized 92 patients with ST-segment elevation MI and
thrombus to the X-SIZER or control. Although there were
no differences in TIMI-3 flow, improvements in the more
sensitive score of myocardial blush were evident, along with
improvements in ST-segment elevation resolution and sig-
nificant reduction in angiographic complications. There are
also trends seen in the recovery of left ventricular function at
discharge and at 30 days. These two trials suggest that distal
protection offers a beneficial role to our SVG and AMI
angioplasty patients.
INFLAMMATION AND PCI
Turning to inflammation and its role in the angioplasty
laboratory, a group at the Cleveland Clinic randomized 75
patients who had elective angioplasty to pretreatment with
300 mg of clopidogrel versus no pretreatment. Dr. Frank
Zidar presented data on the inflammatory markers: C-reactive
protein, CD-40 ligand, P-selectin, and interleukin-6. Plate-From Duke University Medical Center, Durham, North Carolina.
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